Antimicrobial resistance (AMR) is a growing concern worldwide and is recognised as one of the leading health challenges by the World Health Organization (WHO). With drug resistant infections contributing to nearly 5 million deaths every year and costing the European Union (EU) an estimated €1.5 billion per year in healthcare costs and productivity losses, AMR is both a scientific and economic issue.

In this episode, Dr Boumediene Soufi, Head of Antimicrobial Resistance at Sandoz, discusses the challenge of AMR and some of the actions being taken by Sandoz and the wider pharmaceutical industry to address this issue.

Episode ID: 1000587234663

GUID: https://www.europeanpharmaceuticalreview.com/?post_type=podcasts&p=176606

Release Date: 23/11/2022, 14:48:11